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Abstract
Rapid prehospital electrocardiographic diagnosis of myocardial infarction in the
setting of left bundle branch block and artificially paced rhythms is clinically
challenging. Electrocardiographic findings of these conditions can mask classic findings
of myocardial infarction, which can lead to significant treatment delays in these patient
populations. We propose a randomized controlled trial evaluating prehospital
measurement of troponin, in patients with left bundle branch block or paced rhythms,
presenting with symptoms of acute coronary syndrome. We hypothesize that this
prehospital measurement will reduce delays to percutaneous coronary intervention in
patients with myocardial infarction. We will implement the use of point-of-care troponin
assays to be completed by paramedics, with findings relayed to receiving facilities.
Improving rates of early intervention in myocardial infarction has been shown to be
beneficial in reducing morbidity and mortality. Prehospital measurement of troponin
could be uniquely beneficial in patient populations who have low rates of early
intervention.
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Chapter 1: Introduction
Background
Myocardial infarction (MI) is a common, life-threatening illness worldwide. It is a
major cause of death and disability throughout the world.1 The World Health
organization predicts that coronary-related deaths will increase 100% for each gender in
the next 2 decades.2 In the United States, it is estimated that an MI is experienced once
every 43 seconds in the adult population.3 The estimated annual incidence of MI is
730,000 events including new and recurrent attacks.3 MI is defined as myocardial cell
death due to prolonged ischemia.1 It is caused by blockage of coronary arteries, which
supply the muscle of the heart. This blockage can occur by multiple causes, including
plaque rupture, thrombus, atherosclerotic changes, ischemic imbalance, or procedurerelated causes.1 MI is defined within the umbrella term acute coronary syndrome (ACS),
which includes ST segment elevation myocardial infarction (STEMI), non-ST Segment
elevation myocardial infarction (NSTEMI), and unstable angina (UA).4
Myocardial infarction can be recognized by clinical features, including
electrocardiographic changes, elevated biochemical markers, imaging, and pathology.1
STEMI and NSTEMI are distinguished from one another by characteristic changes on a
12-lead electrocardiogram (ECG).4,5 STEMI and NSTEMI can indicate different levels of
severity, and thus have different treatment and management guidelines.5 The role of early
reperfusion in STEMI patients is well established.6-8 Current recommendations from the
American Heart Association (AHA) stipulate that door-to-balloon times for percutaneous
coronary intervention (PCI) should be under 90 minutes in STEMI patients.6
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The need for early diagnosis, and the creation of new technology, has resulted in
changes in the diagnosis and treatment of MI. In many EMS systems, STEMIs can be
identified in the field, and 12-lead ECGs are acquired, and in some cases transmitted to
receiving facilities.8 In a systematic review of 16 studies, this has been shown to
significantly reduce delays to treatment and short-term mortality in the setting of
percutaneous intervention.8 It is clear that decreasing delays to treatment in the acute
phase of MI can lead to better outcomes for patients. System delay in the treatment of MI
can be considered a modifiable risk factor.9 However, ECG is not always the most
appropriate diagnostic tool. The ECG is often insufficient to diagnose MI, as ST segment
changes can be seen in other conditions.1 Some of these conditions include pericarditis,
left ventricular hypertrophy, left bundle branch block, Brugada syndrome, stress
cardiomyopathy, and early repolarization.1,5 The electrocardiographic findings of MI can
also be masked in the presence of an implanted pacemaker.10 For these situations, in
which the ECG alone is not diagnostic of MI, other diagnostic tools become necessary.
Measurement of cardiac biomarkers such as troponin have become essential in the
diagnosis of MI. An analysis of diagnostic data showed that the diagnosis of MI via ECG
has decreased 50% over 40 years, while the amount of MIs diagnosed by cardiac
biomarkers has increased 2 fold.3 Troponin I and T are present in cardiac myocytes, and
are detectable in the blood when myocytes necrose.1 Serial measurements of troponin can
reveal trends which are highly suggestive of evolving cardiac events.11 Sensitive troponin
assays have significantly improved the early diagnosis of MI.12 However, central
laboratory troponin measurements often take about 1 hour to run.13 This amount of time
can be certainly deleterious in the setting of an MI. The measurement of troponin is now
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available via rapid point-of-care devices, which have reasonable correlation with central
laboratory values.13 Point-of-care devices are generally used in the emergency
department of hospitals, however their use has been shown to be feasible in the
prehospital setting.14,15
Patients with bundle branch block (BBB) have ECG findings that can confound
the diagnosis of MI.16 The presence of BBB is increasing as the US population ages.16 It
is estimated that about 100,000 patients with bundle branch block experience MI
annually.17 Bundle branch block can occur in 1-15% of MIs, and in one study of almost
300,000 patients, BBB was found in one out of every 8 patients presenting with MI.18
BBB can present as a de novo finding in acute MI, however BBB is most often a preexisting factor in those experiencing MI.16 Patients with BBB and MI have a 2-fold
increased risk of in-hospital death.18 Furthermore, this increased mortality risk is seen in
all BBB patients, regardless of time of onset or location of the conduction block.19
Patients with BBB and MI have decreased rates of appropriate reperfusion therapy and
experience longer delays to treatment.20
Similarly to BBB, the presence of a paced rhythm from an implantable pacemaker
can make the diagnosis of MI difficult. In 2004, 178,000 pacemakers were implanted in
the US, which was a 19% increase from 1997.21 Pacemakers do not use the natural
conduction system of the heart, causing the QRS complex to appear widened on ECG.22
The characteristic ECG findings of MI can be accentuated, cancelled, or reversed by
changes due to pacing.23 Furthermore, the addition of new types of pacemakers and
variability of pacemaker lead placement make ECG findings less predictable.24 Patients
with pacemakers are generally older and at a higher risk for coronary events.10 In one
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study of over 100,000 patients with MI, 1.9% had paced rhythms, and were found to have
higher rates of crude mortality, and were less likely to receive reperfusion treatment.25
Statement of the Problem
Myocardial infarction is a common life-threatening event in the US and
worldwide, and the incidence is increasing.1-3 The role of early reperfusion, especially in
STEMI patients, has created a need for rapid diagnosis and triage of ACS patients.6-8 The
prehospital ECG has improved rapid diagnosis, triage, and outcomes for patients
presenting with MI.8 However, this rapid diagnosis and triage is not possible for patients
with underlying conditions that confound the electrocardiographic diagnosis of MI.
Patients with BBB and paced rhythms have higher mortality, longer delays to treatment,
and lower rates of overall treatment.18,19,25 These patients require additional diagnostic
modalities, such as the measurement of troponin. Measurement of prehospital point-ofcare troponin in ACS has been studied, but not in a trial of select patients with difficult
prehospital ECGs which may mask characteristic findings of MI. These patients, such as
those with BBB or paced rhythms, could have significant benefit of prehospital troponin
measurement in the rapid diagnosis of MI.
Goals and Objectives
The proposed study is a randomized controlled trial. The study aims to evaluate
the use of point-of-care measurement of troponin in the prehospital phase for ACS
patients with underlying BBB or paced rhythm. The intervention group will have
troponin measured in the prehospital setting, with the value reported to the receiving
facility, and the control group will receive no prehospital labs. The primary outcome for
the study is door to balloon time for percutaneous coronary intervention, to be measured
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in minutes for both the intervention and control groups. Secondary outcomes include:
EMS transport time, symptom onset to first medical contact, diagnosis of MI, qualitative
troponin, PCI status, and stent placement. This study will help determine whether
prehospital measurement of troponin can reduce delays to treatment in a patient
population that is at risk for significant treatment delays and high mortality.
Hypothesis
We hypothesize that in patients with BBB or paced rhythms, and symptoms
consistent with acute coronary syndrome, prehospital measurement of troponin will
significantly reduce delays to treatment, measured in door to balloon time for
percutaneous coronary intervention, compared to a similar population receiving no
prehospital troponin measurement.
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Chapter 2: Review of the Literature
Introduction
A thorough literature review was conducted between July 2014 and August 2015.
Relevant articles were accessed via Ovid MEDLINE and PubMed NCBI databases. Key
search phrases included: prehospital troponin, troponin, cardiac biomarkers, point of care
device, STEMI activation, STEMI, acute coronary syndrome, myocardial infarction,
AHA guidelines, left bundle branch block (LBBB), bundle branch block, paced rhythm,
electrocardiogram, electrocardiographic diagnosis of myocardial infarction, paramedic
interpretation, paramedic skill, ventricular conduction delay, clinical outcomes,
prehospital research, door to balloon time, treatment delay, and system delay. Preference
was given to recent articles less than 10 years from publication date, however, older
articles were included if they were considered essential to the scientific discourse. A
textbook regarding prehospital research was also included.
Left Bundle Branch Block and Myocardial Infarction
The Electrocardiogram in Myocardial Infarction with Bundle Branch Block
The rapid diagnosis of myocardial infarction (MI) in the presence of left bundle
branch block (LBBB) has been studied for over 60 years, due to the unique clinical
challenge it presents.1 A large retrospective study conducted in 1999 by Sgarbossa and
colleagues, evaluated the electrocardiogram (ECG) in the diagnosis of MI.2 The study
was based on existing ECGs of patients with confirmed MI and BBB, compared to
controls of patients with LBBB and no acute MI. The authors created several diagnostic
criteria for diagnosing MI in the context of LBBB. These criteria involve ST segment
changes including ST segment depression, ST segment elevation >1mm in precordial

8

leads, and ST segment elevation >5mm discordant with the QRS complex.2 The
individual criteria have low sensitivity and specificity when used alone, but when used as
part of the index score proposed in the study, the sensitivity and specificity improved.
The sensitivity and specificity were reported as 78% and 90%, respectively, in a
derivation sample. However, the sensitivity dropped to 36% in a validation sample.2
The criteria proposed by Sgarbossa et al. provide an index scale for diagnosing
MI on ECG in the presence of LBBB. However, a sensitivity of only 36% in the
validation sample means that by these criteria alone, many patients with BBB and MI
will not be identified by the criteria. The false negative rate of these criteria may be
unacceptable in many settings. Also, in this study, all ECGs were interpreted by
cardiologists. The authors acknowledge that the proposed interpretation may be more
difficult by generalists, paramedics, or emergency physicians.2 This has large
implications in a real-world setting, where the rapid availability of a cardiologist is not
always commonplace.
The index score outlined by Sgarbossa et al. has been evaluated by multiple
studies since, and is referred to as the Sgarbossa criteria. A 1999 retrospective study
evaluated the use of the Sgarbossa criteria and several other ECG findings in 103
presentations of acute cardiopulmonary symptoms, 83 of which were in patients with
LBBB.3 30% of the patients evaluated met criteria for MI.3 The authors found that using
the Sgarbossa criteria, less than 10% of MIs would have been identified in the cohort, and
the sensitivity of the algorithm was found to be 10% in this study.3 Again, this study
shows that the use of characteristic ECG findings of MI in LBBB patients is difficult, and
the sensitivities of specific criteria or algorithms are low. This study is limited by small

9

sample size, only evaluating about 100 patients and 30 MIs. Furthermore, the ECGs were
all read by a single physician, which may limit the external validity of the study.
A similar 2001 study included 182 patients with LBBB on initial presentation,
and receiving workup for MI, 24 of whom were eventually diagnosed with MI.4 This
study revealed that the index score had a sensitivity of 46% and a specificity of 93%.4
The study divided patients into high, moderate, and low risk groups based on initial
presentation. Of note, only 29% of the patients who were diagnosed with MI were
initially placed in the high risk group.4 This suggests that determining risk in LBBB
patients is difficult, further suggesting the need for quality diagnostic tests. The reported
ECG sensitivity is higher than in previous studies, however, this was again a small study
and external validity is questionable.
A prospective study in 2001 was carried out to establish the diagnostic accuracy
of previously proposed ECG criteria.5 This study included 148 patients with LBBB and
suspected acute MI, and of these patients 48% had confirmed MI.5 Interestingly, this
study aimed to measure the ECG criteria against clinical judgment of providers. Clinical
judgment was defined by decision-making, most notably the initiation of reperfusion by
thrombolysis. The criteria used in this study, based on the work by Sgarbossa et al., had a
sensitivity of 17.1% and specificity of 94%.5 This was compared to clinical judgment,
which had a sensitivity of 15.8% and specificity of 96%, which was noted by the authors
to be not significantly different from the ECG criteria.5 The sensitivities and specificities
reported in this study are certainly lower than those reported in previous studies.5 The
authors explain that this may be due to a lower pretest probability in their study, versus a
pre-test probability of almost 90% in prior, retrospective studies.5 This reveals that
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studies based on the ECG criteria performed in a retrospective manner are prone to
selection bias. The lower pretest probability in this prospective study is likely more
indicative of the ECG criteria performance in a real-world setting. All ECGs in the study
were read by three separate clinicians experienced in ECG interpretation. The criteria
were found to be unsatisfactory for a diagnostic test.5
A meta-analysis performed in 2008 evaluated studies evaluated methods
including the Sgarbossa criteria in the diagnosis of MI in LBBB patients.6 This metaanalysis included all of the above-described studies by Sgarbossa et al., Gunnarson et al.,
Shilpak et al., and Kontos et al. It also included several other studies that included at least
one point of the Sgarbossa index score. The meta-analysis included 2,100 patients total
and found that when a Sgarbossa index score of 3 was met, there was a summary
sensitivity of 20% (95% CI 18% to 23%), and specificity of 98% (95% CI 97% to 99%).6
Due to the high positive likelihood ratio of 7.9, the authors conclude that an index score
of 3 is useful in diagnosing MI.6 It is suggested that when a score of 3 or greater is met, in
the right clinical setting, treatment for MI should be initiated.6 Furthermore, the study
found great intraobserver agreement between studies, suggesting that the criteria can be
used uniformly.
Although the meta-analysis includes the strongest amount of evidence compiled,
there remain some limitations. Sensitivies and specifities for the Sgarbossa criteria
declined significantly when less than 3 criteria were met. When a score of 2 or less
occurred, sensitivities ranged from 20% to 79% and specificities ranged from 61% to
100%.6 Therefore, MI cannot always be ruled out using the criteria. Patients with a lower
index score require more diagnostic testing, which can certainly delay treatment. The
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authors report that a score of 2 or less does not have sufficient diagnostic accuracy.6
Furthermore, in the included studies, ECGs were interpreted by experienced cardiologists
and ED providers, all of whom were prepared to apply the criteria in the study.6 Though
the intraobserver agreement may be great in controlled settings within studies, it may not
be as applicable in settings where providers are less likely to use the criteria on a regular
basis. No study included in the meta-analysis evaluated the criteria in a prehospital
setting.
A 2012 study looked to increase the accuracy of the Sgarbossa criteria, with the
modification of one criterion.7 In lieu of looking at ST segment elevation discordant with
the QRS complex of >5 mm, the study used a proportional measure comparing the ratio
of S segment with ST elevation.7 The study included 162 patients, 129 of whom were in a
control group, and used angiographic endpoints as the criterion standard to evaluate the
presence of MI.7 The authors found that the modified rule significantly increased the
diagnostic accuracy of the ECG in LBBB patients. The sensitivity using the modified
criteria was improved to 91% from 52% using the previous criteria, however, the
specificity declined to 90% from 98%.7 This indicates that the modified rule may
improve ECG criteria to a more realistic and useful diagnostic tool. However, the authors
reveal limitations to the study that limit the use of the more sensitive criterion. First, the
study was small and underpowered to detect small differences in sensitivity.7
Furthermore, the measurement of ratios on ECGs is difficult and not routine for most
providers. These methods may not be feasible in a fast-paced emergency department or
prehospital setting. The authors suggest that the proposed modified rule would need to be
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validated in a larger prospective study.7 Even with more specific ECG findings of MI in
LBBB patients, electrocardiographic diagnosis remains challenging and time-consuming.
Outcomes and Complications in MI and Left Bundle Branch Block
A 1998 retrospective study examined the prevalence and outcomes of patients
with MI and BBB.8 The study was conducted using the National Registry of Myocardial
Infarction 2 which includes over 200,000 patients. The study found that in the database,
RBBB was found in 6.2% (95% CI 6.1-6.3%) of patients, and LBBB was found in 6.7%
(95% CI 6.6-6.8%) of patients presenting with MI.8 Surprisingly, BBB of any location
was found in 1 out of every 8 patients presenting with myocardial infarction. Patients
with BBB and MI were much less likely to receive reperfusion therapy. Patients with no
BBB were 1.7 fold more likely to receive reperfusion therapy over patients with RBBB
(p < 0.001), and 4.2 fold more likely to receive therapy over LBBB patients (p < 0.001).8
BBB patients were also significantly less likely to receive other medical therapies such as
aspirin, beta blockers, heparin, and IV nitroglycerin (p < 0.001 for all associations).8
Furthermore, patients with LBBB were found to have significant delays to thrombolytic
therapy.8 The authors suggest that physicians may not understand the benefit of
reperfusion of BBB patients, and may have difficulty in establishing the diagnosis of MI
in these patients. Perhaps the most important finding of the study is related to the inhospital mortality of BBB patients. The in-hospital mortality rates of RBBB and LBBB
was not significantly different (p = 0.2). However, the in hospital mortality rate of BBB
(RBBB 23%, LBBB 22.6%) patients was almost 2 fold higher than patients with no BBB
(13.1%) (p < 0.001).8
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This study by Go et al. demonstrates the increased risk associated with the
diagnoses of RBBB of LBBB. Both were associated with increased risk of in-hospital
mortality, and decreased rates of treatment. This is a strong study including over 200,000
patients, representing a diverse population from 1571 US hospitals.8 The study does,
however, have some limitations. Notably, the study was not able to determine how many
patients presented with new BBB over pre-existing BBB. New BBB can be seen in acute
MI, but other studies have suggested that it is more often a result of underlying structural
disease.1 The authors suggest that this limitation is perhaps generalizable, as many
patients presenting for care will have BBB of unknown timing.8 High mortality in the
BBB patients may be due to the fact that they are more likely to have predisposing risk
factors such as prior MI, congestive heart failure, coronary artery disease, stroke, diabetes
mellitus, and hypertension.8 However, the lower rates of treatment for treatmentappropriate patients seen in this study, as well as the significant delays for those who
received treatment, could certainly play a role in the higher morbidity and mortality seen.
A 2000 study again used the National Registry of Myocardial Infarction 2 to
understand rates of treatment, specifically in LBBB patients.9 The study found that
patients with LBBB and MI had a low rate of treatment, at 8.4%.9 The rate of treatment
for LBBB patients who presented with chest pain was 4 fold higher than those who
presented without chest pain; however, treatment rates remained low at 13.6%.9 This
suggests that clinical impression is important for physicians in choosing treatment.
However, the most common reason that providers did not choose reperfusion therapy was
due to undiagnostic ECG, which was the reasoning for avoiding therapy in 57% of those
who did not receive treatment.9 Similar to Go et al., the authors found that patients were
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less likely to receive reperfusion therapy, or other therapies standard to the treatment of
MI, within 24 hours of presentation.9 The study also found that patients who were
admitted to the hospital with an initial diagnosis of MI were more likely to receive
reperfusion therapy and had less delay to treatment.9 This suggests that early diagnosis is
associated with higher treatment rates and less delay. However, the authors explain that
patients could not be interviewed, so the presence or absence of chest pain on a chart may
have been entered in error.9 Also, new versus old LBBB could not be determined in this
study. The study does build to the evidence, establishing further that patient presentation
complicates diagnosis and treatment. Notably, undiagnostic ECG was found to be the
most common reason for non-treatment of MI.
A 2011 prospective study was completed to examine the relationship between
LBBB and outcomes in patients with possible acute MI.10 The study involved 401
patients with LBBB, admitted for the rule out of acute MI. Due to the high availability of
prior ECGs seen in this study, the authors were able to estimate new or presumed new
LBBB versus old LBBB. The proportion of new LBBB was 36%, presumed new 28%,
and old 36%.10 Neither the frequency of MI, nor the size of MI, was different among
new, presumed new or old LBBB.10 MI was diagnosed in 116 patients total, 93 of whom
had elevations in troponin and CK-MB.10 As part of the rule-out protocol, all patients
were subject to measurement of cardiac biomarkers as well as use of a routine ECG. Of
the patients diagnosed with MI, only 12 had concordant ST changes on ECG.10 ST
changes used in this study were those outlined by the Sgarbossa criteria. The study had
high treatment rates: 152 patients underwent angiography, 43 had significant disease, and
16 had revascularization.10
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Kontos et al conclude that MI among LBBB patients is rare, and the size of the
MI is relatively small.10 However, the authors did not compare LBBB patients to controls
without LBBB in this study. ST changes were rare in this study, but were associated with
a high likelihood of MI and larger disease.10 The authors conclude that the ECG can be a
good indicator of patients most likely to benefit from reperfusion therapy. This
conclusion is interesting, given that significant disease was present on angiography in 43
patients with positive troponin, while only 12 were found to have ST changes in the
entire study. What is clear, is that a universal activation of the catheterization laboratory
(“cath lab”) for all patients presenting with LBBB and acute coronary syndrome
symptoms would not be cost-effective or beneficial. This study is helpful due to the
prospective nature, as well as the ability to determine new versus old MI. However,
LBBB patients were not compared to controls, and treatment rates were high in the study,
which is not consistent with large registry trials.
LBBB and MI Conclusions
The above reviewed articles suggest that there remains a challenge of diagnosis of
MI in the context of LBBB. LBBB on ECG remains a frequent reason for treatment
delays or false activation of the catheterization laboratory.1 The need for rapid diagnosis
in MI puts pressure on providers to move patients to treatments quickly, but false
activations are costly.11 Criteria have been proposed to aid the diagnosis of MI in the
context of LBBB, but sensitivity for MI has remained low.2-6 The diagnosis of MI in the
context of RBBB is generally more feasible for providers.12 Measurement of S and ST
segment ratios yields higher sensitivity, however this skill is not routinely used in ED
providers.7 Therefore, reliance on ECG alone in the diagnosis of MI would result in many
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missed cases. Patients with LBBB and MI are underserved; they have lower overall rates
of treatment, and higher mortality.8,9 A frequent reason for non-treatment in BBB patients
in the presence of an undiagnostic ECG.3 Diagnosis and treatment in this population
remains challenging, and the use of further diagnostic testing, such as the measurement of
cardiac biomarkers may be necessary.13
Artificially Paced Rhythm and Myocardial Infarction
The Electrocardiogram and Artificially Paced Rhythm in Myocardial Infarction
Early electrocardiographic diagnosis of myocardial infarction in the setting of an
artificial pacemaker is difficult. Similarly to the electrocardiographic morphology LBBB,
the QRS complex is often widened with a paced rhythm, potentially masking
characteristic changes associated with ischemia.14 A study in 2008 examined the paced
electrocardiogram in the setting of ischemia.15 The small study of 15 patients with
temporary pacing compared baseline ECGs to those acquired intraoperatively during
percutaneous coronary intervention (PCI). The authors inflated a balloon in a coronary
artery for one minute, blocking blood flow and mimicking the pathophysiology of a
myocardial infarction.15 Temporary pacing alone, without inflation of the balloon, created
ST changes in 3 out of the 15 patients in the study.15 The study found significant ST
segment deviations during induced ischemia, when compared to pre-PCI ECGs.15 This
study shows that ST segment changes can be seen in the paced rhythm, either as a result
of ischemia or as a secondary change due to pacing alone. However, the real-world
application of this study may be limited. The study used temporary pacing, which may
not be indicative of potential changes during permanent pacing. Another limitation is that
ischemia was only induced for one minute with balloon inflation.15 One minute of
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ischemia is not typical of patient presentation in MI. This study only examined ECG
changes seen in very early ischemia, and cannot necessarily characterize ECG patterns in
patients experiencing prolonged ischemia.
A 1996 study by Sgarbossa et al. used the GUSTO-1 database to examine patients
with paced rhythm. They found that of the 41,021 patients in the database, only 32
(0.1%) had ventricular paced rhythms and enzymatically confirmed MI.16 The ECGs of
these patients were compared to those of randomly selected patients with confirmed
stable coronary artery disease and ventricular pacing. The authors found that the ECG
finding most predictive of acute MI in paced patients was ST segment elevation >5 mm
in leads with predominantly negative QRS complexes. This finding had a sensitivity of
53% and specificity of 88% (positive likelihood ratio 4.41, p = 0.025, relative risk 2.35,
95% confidence interval 1.26 to 4.39).16 The sensitivity and specificity are reasonable
and the authors suggest that it is a useful diagnostic tool. However, the study involves a
very small number of patients from a large database. The small incidence of pacing in
this outdated database is likely not representative of the general population, as the
placement of pacemakers has increased.17 Furthermore, ECGs in this study were
compared to controls, not previous ECGs. Varied placement of pacemaker leads results in
different QRS morphology in each patient.18 As a result, comparison of ECGs to controls
is less accurate than comparison to baseline ECGs, which was not possible in this study.
A 2004 case report discussed the potential downfall of relying on the abovediscussed ST segment changes in the setting of paced rhythms. The case report discusses
two cases of patients with pacemakers, both shown to have ST segment elevation >5 mm
in at least one lead.19 However, these patients were not experiencing MI, and had ST
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segment elevations at baseline.19 The use of ST segment elevation alone in the diagnosis
of MI in these patients could result in unnecessary treatment and cost. Identification of
MI is difficult, as ECG changes induced by ischemia can be accentuated, cancelled, or
even reversed by secondary changes due to pacing.19 A 1999 case report examined two
patients with pacemakers, who were found to have MI by examining serial ECGs.14 In
these cases, providers had access to previous ECGs, which proved helpful in the eventual
diagnosis of MI. The authors explain that because the majority of paced rhythms
originate in the right ventricle and do not travel through the normal conduction system,
their morphology is similar to that of LBBB.14 The authors conclude that the diagnosis of
MI by ECG in paced rhythms is difficult, and relies on experienced providers.
The electrocardiographic diagnosis of MI can be further complicated in the setting
of a paced rhythm due to the variability of pacemakers, intermittent pacing, or
biventricular pacing.18,20 A 2012 case report discussed the ECG in a biventricular paced
individual presenting with MI.20 ST changes were seen when compared to baseline ECG
and an eventual diagnosis of MI was made.20 However, the diagnosis was aided by high
suspicion of MI due to cardiogenic shock, characteristic symptoms, and availability of a
prior ECG. The authors note that criteria outlined by Sgarbossa et al. likely do not
translate to patients with biventricular pacing.20 The variability of pacing methods, as
well as differing patient presentations, confounds the diagnosis of MI in many cases.
A 2010 study aimed to build on the 1996 data by Sgarbossa et al. The authors
reviewed a total of 159 ECGs, 57 of which were paced rhythms with confirmed MI, and
101 of which were controls.21 The most specific criterion was found to be ST segment
elevation >5 mm discordant with the QRS complex. The authors found that for this
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criterion, sensitivity was 10% (95% CI 5% to 21%), and specificity 99% (95% CI 93% to
99%).21 The specificity of this finding is strong, making the test useful for a diagnosing
MI, but it is not useful as a rule-out test due to the very low sensitivity.21 This is
consistent with prior studies on ECG and paced rhythm in MI, where some findings are
highly suggestive of MI but are not seen in a large number of patients. The study adds to
the literature due to its larger sample size. However, it remains a retrospective study
which relies on accurate data entry, and the ECGs were read by experienced users. The
application of specific ECG criteria in a real-world emergency department is more
difficult than in a controlled retrospective study.
Outcomes and Complications in Paced Patients with Myocardial Infarction
A retrospective analysis of over 100,000 patients with confirmed MI found a
prevalence of pacemakers in 1,954 patients (1.9%) presenting with MI.22 The study was
completed in 2001, with data pulled from patients presenting for care from 1994 to 1996.
The study found that patients with paced rhythms were more likely to be older and male,
and more likely to have a previous diagnosis of MI and cerebrovascular disease.22 Paced
patients were significantly less likely to receive aspirin at admission (relative risk (RR)
0.91, 99% CI 0.88 to 0.94), or beta-blockers at admission (RR 0.89 99% CI 0.82 to
0.96).22 These patients were also significantly less likely to receive reperfusion therapy
(RR 0.27, 99% CI, 0.22 to 0.33).22 The authors examined these treatment rates in
treatment-appropriate patients. It is clear that they are less likely to receive the standard
of care when compared to patients presenting without paced rhythms.
The above study also evaluated hospital outcomes in the cohort of patients
presenting with MI and paced rhythm. Paced patients were more likely to experience
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death in the hospital, at 30 days, and at 1 year (P≤0.002 for all associations).22 Paced
patients were also more likely to experience congestive heart failure or reinfarction
during initial hospital stay (P<0.001 for both associations).22 It is reasonable that patients
who are generally sicker and older on presentation, as was seen in the paced patients, had
higher rates of mortality and complications. However, increased risk for mortality was
adjusted for illness severity and treatment, including admission and discharge medication.
The risk of 30-day mortality remained significant when adjusted for illness severity (RR
1.10, 95% CI 1.00 to 1.20), but fell slightly below sigificance when adjusted for illness
severity and all treatment (RR 1.03, 95% CI 0.93 to 1.14). Risk of long-term mortality
remained significant when adjusted for illness severity and all treatment (RR 1.12, 95%
CI 1.06 to 1.18).22 The authors suggest that some differences in treatment are potentially
due to the difficulty in rapid diagnosis of MI in the setting of a paced rhythm. The
decreased mortality risks when adjusted for treatment indicate that mortality rates could
be improved by better and more consistent treatment of individuals with paced rhythms
and MI.22
The above study is important and helpful in quantifying the prevalence of paced
rhythms in MI, as well as the treatment and outcomes of these patients. However, as a
retrospective study, data accuracy is not within the control of the writers. Furthermore,
the data presented in this study were from 1994 to 1996, and may not be representative of
the current population, as the incidence of pacemakers has increased. The study was also
not able to determine differences between ventricular and atrial pacing, and it could not
be determined whether all patients were paced during acute MI.22 However, large study
numbers, and adjustment for illness severity and treatment, aids analysis.
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Pacemaker and MI Conclusions
As in LBBB, the electrocardiographic findings of paced rhythm complicate the
diagnosis of MI.14,15,17 Incidence of MI in paced patients is difficult to quantify given an
increasing amount of pacemaker placements.17 Above reviewed studies indicate the
incidence of paced rhythm in MI to be around 0.1% to 1.9%.16,22 There are findings on
ECG of a paced rhythm that are highly suggestive of MI, but are seen in a low number of
patients.16,21 This means that use of ECG only in the triage of paced patients, like in
LBBB, would lead to missed MIs or delayed treatment. Furthermore, the application of
specific ECG criteria is difficult for general physicians.23 Patients with paced rhythms
and MI have lower rates of standard treatments, are significantly less likely to receive
reperfusion therapy, and have a higher risk of mortality.22 Difficulty in the diagnosis of
MI in these patients and reduced overall treatment indicates a need for diagnostic tests
other than the ECG.
Prehospital Triage in Myocardial Infarction
The Prehospital ECG in STEMI
Prehospital diagnosis and triage of STEMI has advanced greatly due to the
availability of the ECG in a larger number of settings. A study conducted between 2004
and 2007 examined the use of prehospital ECGs in STEMI patients presenting from both
rural and urban environments.24 The study involved 1049 patients, 875 of whom
presented to the hospital via EMS transport.24 In the prehospital cohort, ECGs were
transmitted to receiving hospitals and read by physicians. Physicians and EMS had the
option to re-route EMS transport directly to centers for PCI in patients with high
suspicion of STEMI on ECG. The study evaluated a performance measure of EMS to
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balloon time of <120 minutes. Eighty six percent of patients with prehospital diagnosis
met the <120 minute guideline, compared to only 32% of patients without prehospital
diagnosis (p<0.001).24 Long term all-cause mortality was lower in patients with
prehospital diagnosis compared to those without, 18% vs 31% (log-rank P = 0.003), an
association that remained when the authors adjusted for patient characteristics (hazard
ratio 0.68, 95% CI 0.48 - 0.96, P = 0.028).24
The above study is strong evidence to support the prehospital diagnosis of STEMI
in reducing delays to treatment and mortality. In the course of the study, the proportion of
patients who were diagnosed prehospitally increased, indicating a quick adoption of the
new technology.24 However, the impact of this changing treatment environment on the
results of the study is difficult to determine. The authors also reveal that mortality data in
the study is inherently limited due to a selection bias between groups.24 The study
presents strong evidence for the prehospital diagnosis of MI.
Multiple studies have examined the expansion of prehospital diagnosis of STEMI
to include a direct activation of PCI laboratories by EMS, and a bypass of the emergency
department. A 2011 prospective study included 195 patients transported by EMS who
received PCI.25 Ninety-five of these PCI patients were transported to the ED, and 80 were
transported directly to the PCI center by bypassing the ED.25 For the group triaged
directly to the PCI center, door to balloon time was 35 minutes (95% CI 31 to 36),
compared to 83 minutes (95% CI 79 to 89) in the group without ED bypass (p<0.001).25
The proportion of patients meeting the 90 minute door to balloon guidelines increased
from 28.4% to 91.3% through implementation of the direct referral to PCI.25 The study
included ECG training for paramedics participating in the study, and a maximum of 3
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paramedic interpreted ECGs. Notably, the number of false activations for PCI activation
in this study was 12, the majority of which were due to pre-existing ECG abnormalities.25
This indicates that the activation is inappropriate for patients with pre-existing conditions
which may mimic STEMI, such as BBB and paced rhythm. This is a small study that was
conducted in a single geographic area with a group of highly trained paramedics. The
reproducibility of these results may be limited in areas and systems with fewer resources.
However, the study is further strong evidence of how prehospital diagnosis and triage can
significantly improve in-hospital delays.
Another study published in 2013 evaluated STEMI patients presenting to a single
emergency department by multiple means including EMS transport with PCI activation,
EMS transport without PCI activation, and self-presentation to ED.26 The study included
38 EMS activations of the PCI lab, 47 non-activation STEMIs, and 28 walk-in STEMIs.26
The mean door to balloon times were 37 (±17) in the PCI activation group, 87 (±40) in
the non-activation group, and 80 (±23) minutes for walk-ins.26 Also, compliance with 90
minute door to balloon times were 100%, 72% and 68%, respectively. This study used
the paramedic as the decision maker in activation of the cath lab. The authors did take
measures to control for false positive activations. In this study protocol, patients with
widened QRS complexes > 0.12 seconds were ineligible for prehospital cath lab
activation. This protocol was to avoid false positive activation due to STEMI mimics
such as BBB. Therefore, the benefits of paramedic-centered early activation of PCI seen
in this study are not available to patients presenting with pre-existing ECG abnormalities.
The study does however indicate the potential of a paramedic-centered system in the
rapid diagnosis and triage of MI.
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Several other studies have evaluated the use of paramedics as the main decisionmakers in STEMI triage. A 2014 study retrospective study of 1933 cases compared
prehospital cath lab activation versus cath lab activation within 5 minutes of first inhospital ECG.27 The study found prehospital activation associated with door to balloon
times 14 minutes shorter (95% CI 11 to 17 minutes) than in-hospital activation.27 The
prehospital false activation rate was 33%.27 Computerized ECG interpretation aided
paramedics in diagnosis of STEMI, so evaluating paramedic skill in ECG interpretation is
difficult. The high prehospital false activation rate in this study may deter systems from
adopting similar methods due to cost. STEMI mimics such as BBB or paced rhythms
may be excluded from activation criteria, again demonstrating limited access to early
diagnosis of MI in patients with pre-existing ECG abnormalities. A 2011 study
evaluating prehospital triage showed false activation rates of 25% even when paramedics
received additional training focusing on STEMI identification and differentiation of
STEMI mimics.28 The authors cite paramedic ability to distinguish presence or absence
of ST elevation in ECG with LBBB as a specific concern.28
To review prehospital ECG in the treatment of STEMI, a meta analysis was
conducted in 2014.29 The review included data from 16 studies, comprising about 14,000
patients. The analysis included studies from differing geographic locations, and EMS
protocols. Notably, the studies comprised multiple methods of advanced notification of
STEMI.29 The authors found that prehospital 12-lead ECG and advanced notification was
associated with a 39% relative risk reduction in short-term mortality when compared to
standard or no prehospital cardiac monitoring (risk ratio 0.61, 95% CI 0.42 to 0.89;
P=.01).29 For this outcome measure, low heterogeneity was observed between studies.

25

The 39% relative risk reduction in short term mortality is strong evidence for the use of
early diagnosis and advanced notification of STEMI by EMS personnel. 12-lead ECG
and advanced notification was associated with a mean 38.66 minute reduction in door to
balloon time (95% CI -50.75 to -26.57, P<0.000001).29 Door to balloon times were
heterogeneous between studies, but significant reductions were seen in all but one study.
This analysis presents a large pool of significant data supporting the use of prehospital
notification in reducing delays to treatment. Methods varied between individual studies,
which potentially threaten the internal validity of the analysis. However, study variability
may aid the external validity of the analysis, due to a variety of EMS and hospital
protocols that currently exist.
Limitations of the Prehospital ECG
As discussed above, the benefit of the prehospital ECG and advanced notification
to hospitals is well established. However, prehospital diagnosis and triage is difficult, and
challenges remain. Multiple studies have assessed paramedic ability to identify true ST
segment elevation on 12-lead ECG. A 2008 study assessed the ability of paramedic
students to distinguish ST elevation on isolated leads.30 The survey included four isolated
ECG tracings, three of which showed ST segment elevation. Only 10% of students
correctly interpreted all four tracings, and recognition of ST elevation varied from 3880% in the different tracings.30 These reported accuracies are not ideal and could lead to
poor performance of prehospital ECG and advanced notification. However, this study
was conducted on students only, and did not allow for paramedic interpretation of a 12lead ECG.
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Paramedic assessment of STEMI becomes more complicated when confounding
factors such as STEMI mimics are present on the ECG. A 2002 study showed that the
paramedic true positive rate for STEMI was 60% when no confounding factors were
present, and dropped to 36% when confounders were present.31 ECG confounders were
defined as prior acute MI, poor ECG quality, BBB, fascicular block, left ventricular
hypertrophy, and paced rhythm. The study found that cardiologists were significantly
more likely to be accurate when confounders were present.31 A 2013 study evaluated ST
segment elevation recognition in almost 500 practicing paramedics.32 Paramedics were
asked to evaluate 10 12-lead ECGs, which included STEMI, normal ECGs, and STEMI
mimics such as LBBB and paced rhythms. Overall STEMI detection sensitivity was 75%
(95% CI 73% to 77%) and specificity was 53% (95% CI 51% to 54%).32 Much of the
inaccuracy in this study was due to misinterpretation of STEMI mimics as STEMIs.
Furthermore, the paramedics included reported recent ECG training and generally high
confidence in interpreting ECGs.32 The authors suggest that the results of this study show
the potential for many STEMIs missed in the field, as well as many false activations of
the cath lab.32 This study did not assess paramedic ability to recognize MI superimposed
on pre-existing ECG abnormalities such as LBBB or paced rhythms.
Prehospital ECG and Triage Conclusions
It is clear that the development of prehospital systems including implementation
of 12-lead ECG, advanced notification of STEMI, and activation of PCI are associated
with reduced delays to treatment.25-29 System delay in the treatment of MI can be
considered a modifiable risk factor.33 Longer door to balloon times are associated with
increased risk of mortality.34 A meta-analysis showed that the prehospital 12-lead ECG is
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also associated with a significant reduction in risk of short-term mortality.29 However,
paramedic recognition of ST elevation on ECG is difficult, and sensitivities are relatively
low.30-32 Furthermore, paramedics are less accurate in diagnosing STEMI when
confounding factors are present, such as LBBB or paced rhythm.31 Many systems
currently exclude BBB and paced rhythms from PCI activation protocols, due to the
difficulty in interpreting the ST segment. Therefore, paced patients and LBBB patients do
not benefit from the early activation and improved treatment noted in STEMI patients.
Cardiac Biomarkers in the Diagnosis of MI
In-Hospital Troponin Assays
The ability to measure levels of sensitive cardiac biomarkers has certainly
improved the diagnosis of MI. The enzyme CK-MB has been used for years, however
troponin has overtaken its use, with even the earliest generations of troponin assays
having a higher sensitivity than CK-MB.35 However, multiple troponin assays exist,
mainly troponin I (TnI) and troponin T (TnT). A large meta-analysis conducted in 2013
evaluated the diagnostic accuracy of multiple cardiac biomarkers.36 The analysis used 21
studies regarding TnI to estimate the pooled sensitivity for MI as 77% (95% predictive
interval 29% to 96%) and the sensitivity as 93% (95% predictive interval 46% to
100%).36 The authors also evaluated TnT using 11 studies, reporting sensitivity for MI as
80% (95% predictive interval 33% to 97%) and specificity as 91% (95% predictive
interval 53% to 99%).36 These values show troponin to be a valuable diagnostic tool.
Measurement of CK-MB, troponin I, or troponin T is currently a Class I recommendation
for all patients presenting with signs and symptoms suggestive of MI.37
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The development of sensitive troponin assays has allowed for earlier detection of
more modest elevations in troponin.38 In most cases, a positive troponin is defined as a
qualitative value above the 99th percentile of a reference adult population.38 The
measurement of troponin is useful in populations with a high pre-test probability of MI.38
An isolated measurement of troponin is not often used as the sole marker of MI. Troponin
values are combined with signs, symptoms, and other diagnostic measurements such as
the ECG. Furthermore, troponin is most often repeated, as rise or fall in troponin is highly
suggestive of an evolving cardiac event.38 Troponin can be elevated in other disease
processes such as chronic kidney disease or congestive heart failure, however troponin
rises more rapidly in acute MI than in these other conditions.38
Point-of-care Troponin Assays
Measurement of sensitive cardiac biomarkers is helpful in the diagnosis of MI.
However, a reliance on hospital central laboratories to measure troponin can lead to
significant delays to treatments in patients, usually taking about one hour to run.39 Acute
MI can evolve rapidly, and an effort has been made to measure troponin more quickly
without sending blood samples to a central laboratory.40 Point-of-care (POC) devices are
now used in many emergency departments to speed diagnosis and triage. A 2009
retrospective study examined the care of patients in the Can Rapid Risk Stratification of
Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the
ACC/AHA Guidelines (CRUSADE) database to determine usage patterns of POC
troponin measurement.40 The authors found that hospitals using POC had significantly
shorter ED stays (p<0.0001).40 This may be due to reduced delays to admission or
discharge as a result of quicker troponin results. Patients with positive POC troponins
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were also more likely to receive standard treatment such as aspirin, beta-blockers, and
heparin (p<0.0001 for all associations).40 The study did not directly measure door to
balloon time or specific treatment time measurements. Patients with positive troponin in
this study were less likely to receive PCI than those with negative troponin (p<0.0001).40
However, the CRUSADE database involves patients with NSTEMI and UA, for whom
the care is less time-sensitive. The data from this study are likely not generalizable to
STEMI or STEMI-equivalent patients. Another study in ACS patients without ST
segment elevation showed that POC troponin was associated with a decreased time to
anti-ischemic therapies of about 45 minutes (p<0.001).41
A potential danger of using point-of-care devices in the diagnosis of MI is the
potential for inaccuracy. The performance of POC devices has been the focus of multiple
studies. A 2013 retrospective trial assessed the accuracy of four POC devices versus
central laboratory results.42 The authors found that devices differed significantly with
respect to sensitivity and specificity in the diagnosis of MI.42 POC assays were less
accurate than central laboratory results, but sensitivities improved with multiple spaced
measurements and all four POC devices had strong negative predictive values.42 This
study is an important look at POC device accuracy. However, the study used banked
heparinized plasma rather than whole blood, which does not represent typical use in the
ED. A 2013 study looked to improve sensitivity of POC devices by reducing the cutoff of
positive results to 50% of the 99th percentile value.43 The authors found that reducing the
cutoff did significantly improve sensitivity of the assays, but it also contributed to a
significantly higher rate of false positives (p<0.0001).43 While the improvement in
sensitivity contributes to fewer missed MIs, a higher rate of false positives can add
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significant cost and treatment-associated morbidity. This study did not assess the
accuracy of POC devices at multiple time points, and rather used single draws.
A 2009 prospective study evaluated the use of POC troponin assays in an
emergency department.39 Loten et al. examined data from 474 uses of an Abbott i-Stat
POC device, by both trained and untrained operators. The authors found that occasional
users of the i-Stat can obtain accuracy similar to trained users (Spearman correlation
0.82).39 The accuracy of the i-Stat when compared to central laboratory was not ideal, but
acceptable with Spearman values of 0.76 to 0.83.39 With a positive troponin cutoff set at
0.01 ng/dL, the specificity of the device was compared to central laboratory was 91%.39
Subject numbers in this study were relatively small, but the study is useful in that it can
be considered a more accurate representation of a real emergency department. It is clear
that the i-Stat is not as accurate as central laboratory, but this study revealed reasonable
correlation and acceptable accuracy among a variety of experienced and inexperienced
users.
Use of POC Troponin Assays in the Prehospital Setting
Due to the rapid and portable nature of POC devices, their use has been studied on
ambulances. The use of troponin measurement in the prehospital phase of care has the
potential to speed triage and allow for quicker treatment for patients with MI.44 POC
devices were not designed with the intent to be used in moving ambulances, therefore
their use in this setting requires validation. A 2013 study aimed to examine correlation
between POC troponin measurement in a moving ambulance and POC values obtained in
an emergency department.44 The researchers simultaneously ran 42 sets of whole blood
samples in two separate settings: in a moving ambulance and in an ED. There was no
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significant difference between the two groups (intraclass correlation coefficient 0.997;
95% confidence interval 0.994 to 0.998; p < 0.005).44 This study did not assess the
clinical application of prehospital troponin assays, but is strong evidence to support high
correlation with in-hospital POC assays.
A study conducted from 2008-2009 included prehospital troponin assays on
almost 1000 patients presenting to an emergency department in Denmark.45 The POC
troponin assays were completed by 11 paramedics trained on the device and rotated
between 70 ambulances. Results of the qualitative prehospital assay were reported to an
on-call cardiologist. Nine hundred and fifty eight patients received prehospital troponin
measurements, and of these patients 208 were eventually diagnosed with MI.45 Of the
patients eventually diagnosed with MI, positive prehospital troponin was reported in 32%
of STEMIs, 30% of NSTEMIs, and 26% of BBB MIs.45 These results are much less
accurate than in-hospital measurements within the same group which identified 73% of
STEMIs, 82% of NSTEMIs, and 83% of BBB MIs.45 The most likely factor relating to
the low sensitivity of the prehospital measurement is that a cutoff of 0.1 ng/dL was used.
Sensitivities have been shown to improve with much lower cutoffs such as 0.01 ng/dL.39
Furthermore, a large number of patients in this study had less than 6 hours of symptoms
prior to the prehospital draw. Notably, nine patients in the study were referred directly for
PCI based on positive prehospital troponin due to equivocal ECG or BBB on ECG.45 The
authors explain that the benefit of the test is most important in this population. This study
is an important demonstration of the feasibility of implementing POC devices
prehospitally.
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A 2011 study evaluated the use of prehospital troponin measurement in a group of
suspected ACS patients.46 Paramedics were trained to complete the test, and were
instructed to do so on all willing patients receiving prehospital ECGs for suspected ACS.
Overall, 985 patients received prehospital troponin measurements in one year.46 The
results of the measurement were not used in triage or patient managment decisions. The
prehospital troponin had a sensitivity of 39% (95% CI, 32% to 46%).46 However, again
the sensitivity of the assays may have been improved by lower detection cutoffs, as this
cutoff in this study was set at 50 ng/L. The study did find that positive prehospital
troponin was associated with higher mortality.46 The authors conclude that the low
sensitivity observed in this study does not justify the use of prehospital troponin as a tool
for triage, but that the measure should be further studied in high risk patients.46 The study
does again demonstrate that the use of POC devices in the prehospital setting is feasible.
Troponin and MI Conclusions
The use of troponin assays in the diagnosis of MI is commonplace, and its use as
a diagnostic tool is well supported.36 Serial measurement of troponin can reveal trends
that are diagnostic of cardiac events.38 Point-of-care devices that measure troponin have
been implemented in many emergency departments to aid in the diagnosis of MI.
Accuracy of POC devices varies among manufacturers.42 However, sensitivity of the
devices increases when cutoffs for positive results are decreased.43 Because this is
associated with a higher rate of false positives, troponin results should be considered in
clinical context. The use of POC troponin devices has been studied in the prehospital
setting, where their use has been shown to be feasible.44-46 Sensitivities of prehospital
troponin have been low in these studies, but could be improved with lower troponin
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cutoffs. The benefit for prehospital troponin is likely strongest in patients with MI and
non-diagnostic ECG.46
Review of Additional Relevant Methodology
PCI Superiority
In the treatment of acute MI, primary PCI is generally superior to fibrinolysis.47
An American Heart Association executive summary contains a Class 1 recommendation
for the use of PCI in STEMI patients.37 Primary PCI has also been shown to be superior
to thrombolysis in a study of patients with paced rhythm.48
Considerations in Prehospital Research
Prehospital research entails a unique set of challenges, but the potential to
investigate complex, system-based questions.49 However, research in the prehospital
setting occurs in an inherently less controlled environment than in-hospital research.49
Due to these challenges, prehospital research is often less understood or accepted by the
research community. However, research is very important to the field of emergency
medicine. High-quality prehospital research requires a clear and simple question to be
answered, and an appropriate study design.49 A majority of prehospital research has
focused on the treatment of cardiac arrest and trauma, but the potential exists for studying
many other aspects of care; notably in systems-based research.50
Prehospital Randomization
Randomization of patients into control and intervention groups is difficult in the
prehospital setting, but there are multiple methods available to researchers.51 Studies have
used computerized randomization, dispatch-controlled randomization, or pseudorandom
techniques such as using even or odd days for group assignment.51 A study of automated
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versus manual chest compressions in cardiac arrest used a method of cluster
randomization.51,52 In this study, randomization was achieved through the allocation of
the automated chest compression device to certain ambulances. It is possible to achieve
randomization through this technique, though there is potential for bias in the selection of
certain ambulances.51 In the above study, the researchers used a cross-over design to
reduce bias.52
Prehospital Consent
Obtaining consent for inclusion in a study is one of the most challenging aspects
of prehospital research.51,53 In some cases, prehospital consent can be obtained by EMS
providers, provided that they are trained in this protocol.53 There are challenges with bias
when consent is obtained in the prehospital setting. Providers may feel uncomfortable
obtaining consent, and may choose to avoid enrolling patients.53 Patients may feel
pressured to agree to enroll, feeling that they may receive inferior care if they do not.53
There are modified consent structures when obtaining consent is not possible or
unnecessary. A waiver of informed consent may be applied when inclusion the study
implies minimal risk of harm.53 This is generally applied to observational studies, as
determining risk is often the goal of prospective trials. Exception of informed consent can
be applied when a life-threatening condition is present and the patient is not able to
provide consent.53 All consent structures require approval from an IRB.
Conclusions
It is clear that the diagnosis of MI is difficult in the context of LBBB and paced
rhythm.2-6 LBBB patients with MI have also been shown to have lower rates of treatment,
longer delays to treatment, and higher overall risk of mortality.8,9 Patients with implanted
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pacemakers and MI have also been found to have lower treatments and higher risk of
mortality.14,15,17 Undiagnostic ECG in these circumstances is problematic, as delays to
treatment have been found to be detrimental to patient outcomes.22 Prehospital care has
contributed greatly in the care of STEMIs, but paramedic ability to recognize STEMI
varies, and is especially difficult when ECG confounders are present.30-32 As a result,
patients with pre-existing ECG abnormalities are undertreated and experience more
delays to treatment. The use of troponin aids diagnosis of MI, and has been studied in the
prehospital setting.44-46 However, the most obvious group that may benefit from
prehospital troponin measurements are those without diagnostic ECGs due to pre-existing
abnormalities. No study has evaluated prehospital troponin specifically in this population.
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Chapter 3: Study Methods
Study Design
The proposed study is a prospective, randomized clinical trial to examine the
efficacy of implementing prehospital troponin measurement in reducing delays to
treatment for chest pain patients with pre-existing electrocardiographic abnormalities.
Study Population and Sampling
Inclusion Criteria
Paramedics will use the following inclusion and exclusion criteria to assess
patient eligibility for study inclusion. Eligible patients will be over the age of 18,
presenting to EMS with symptoms of acute coronary syndrome (ACS). ACS symptoms
in this study are defined as paramedic impression of ACS including any combination the
following: chest pain or pressure, shortness of breath, jaw pain, dizziness, nausea, or
sweating. Eligible patients will have evidence of left bundle branch block (LBBB) or
paced rhythm on prehospital 12-lead ECG. LBBB in this study is defined as: known
history of LBBB or paramedic interpretation of LBBB with or without the aid of
computerized ECG interpretation. Paced rhythm will be defined as known history of
pacemaker placement, or paramedic interpretation of paced rhythm with or without the
aid of computerized ECG interpretation.
Exclusion Criteria
Exclusion criteria include lack of any inclusion criterion, prehospital death, or
cardiac arrest.
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Catchment Area and Statistics
Patients will present to a single EMS agency, American Medical Response
(AMR), in the greater New Haven and Bridgeport, Connecticut areas. Patients will be
transported to Yale New Haven Hospital (YNHH) in New Haven, Connecticut, or
Bridgeport Hospital (BH), in Bridgeport, Connecticut. AMR provides ambulance
transport for eight towns in the greater New Haven area (New Haven, East Haven, North
Haven, Hamden, West Haven, Orange, Woodbridge, Bethany) with a combined
population of 330,000. AMR provides primary EMS service for Bridgeport and Fairfield
Connecticut, as well as mutual aid services for Stratford, Monroe, Trumbull, Easton and
surrounding communities. The Bridgeport/Fairfield division of AMR accounts for about
45,000 calls annually. YNHH and BH each account for around 200 PCI procedures per
year from STEMI activations alone.
Baseline Characteristics
Both intervention and control groups will be assessed for baseline characteristics
including: age, sex, cardiovascular medical history, cardiovascular risk factors, presence
of LBBB, and presence of paced rhythm. Baseline characteristics will be assessed via
patient electronic medical record.
Subject Protection and Confidentiality
Subject Protection and Confidentiality
The study design and protocol will be reviewed by the Yale University Human
Investigation Committee (HIC), which governs studies at both YNHH and BH. See
Appendix A for human investigation consent form. Enrollment in the study is voluntary,
and the need to obtain consent will not be waived for any reason. Patients will be
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assigned a unique identification number. Investigators tasked with analyzing study data
will not have access to patient names or identifiers, and will use only the unique
identification number. Patient data will be analyzed using locked computers compliant
with Health Insurance Portability and Accountability Act (HIPAA) regulations. All
investigators will be required to complete online training regarding HIPAA and Human
Investigations. Patients will have the ability to withdraw from the study at any point
during the study period.
Recruitment
Because this proposed study involves patients in the prehospital setting,
paramedics will be used to obtain consent from patients. As this is not a common practice
for paramedics, all paramedics involved in the study will receive supplemental training
regarding HIPPA and Human Investigations. See Appendix B for an outline of
supplemental paramedic training. Each paramedic will also be required to demonstrate
ability to obtain informed consent, outlining risks and benefits to patients, in the presence
of the principal investigator (PI). Once in the hospital, each patient will meet with a
member of the research team. At this time, if it becomes apparent that a prehospital
explanation of consent did not correctly outline all risks and benefits, patients will be
given the opportunity to immediately withdraw from the study, and the paramedic who
obtained consent will be re-trained.
Study Protocol
Sampling and Randomization
Paramedics will assess eligibility for the study using the above inclusion and
exclusion criteria. Following successful training of all New Haven and Bridgeport AMR
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paramedics, Abbott i-Stat devices will be distributed. The i-Stat is the same POC device
used to measure troponin in the YNHH and BH EDs. The majority of AMR advanced life
support (ALS) units are ambulances staffed by one paramedic and one EMT. Other ALS
vehicles include “fly cars” and supervisor vehicles, of which three to four are staffed at
any time. The i-Stat device will be placed on half of the vehicles assigned to paramedics.
If a vehicle has an i-Stat on board, paramedics will complete a prehospital troponin draw
on eligible patients, comprising the intervention group. Paramedics will not complete a
prehospital troponin draw on eligible patients if their vehicle does not contain the i-Stat
device, and these patients will be entered into the control group. The i-Stat devices will
be pulled and tested every 6 months during the study, and at these time points they will
be switched to the eligible paramedic vehicles that were without an i-Stat device during
the previous 6 months of study, in a cross-over design. This switch will aid in reducing
selection bias by allowing for intervention and control group patients to be enrolled
simultaneously, by varied providers in a larger geographic area. 12-lead ECG and
computerized interpretation will be acquired using LIFEPAK models 12 or 15; the only
models currently in use by AMR in Connecticut.
Control Group
The control group in this study will comprise patients with LBBB or paced
rhythm and ACS as interpreted by a paramedic. The control group will receive routine
care, including acquisition of 12-lead ECG, and ACS care according to state EMS
guidelines.
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Intervention Group
The intervention group will comprise patients with LBBB or paced rhythm and
ACS as interpreted by paramedics. The intervention group will receive a prehospital
blood draw and troponin T measurement performed by a trained paramedic using the
Abbott i-Stat device. Paramedics will receive training on the i-Stat device as outlined in
Appendix B and C. The patients in the intervention group will also receive routine care as
in the control group. Once the POC troponin assay has been completed, the quantitative
result will be immediately relayed to the receiving ED. EMS will not activate the cath lab
based on positive troponin, to avoid false positive activation of PCI. Further care will be
determined and provided by ED providers or consulting physicians should they become
involved.
Outcome Measures
As the primary goal of the study is to assess potential reduction in delays to
treatment, patients will be followed only during the admission in which they were
enrolled in the study. There will be no long-term follow-up for patients. The primary
outcome is door to balloon time, to be measured in minutes. Door to balloon time will be
assessed by data in the electronic medical record. Door time will be defined as time of
ED entrance (the time at which the triage nurse creates the patient record immediately
upon entry into the ambulance bay), balloon time will be defined as the time of balloon
inflation during PCI (as recorded by the cath lab staff), and door to balloon time will be
defined as the difference between these time points. Secondary outcomes include: PCI
status, diagnosis of MI, in-hospital mortality, prehospital troponin, in-hospital troponin
and EMS arrival at scene to balloon time. PCI status will be operationalized as a

46

dichotomous variable, indicating PCI procedure or no procedure. Prehospital troponin
and in-hospital troponin will be operationalized as positive or negative using the YNHH
cutoff of 0.01ng/dL.
Sample Size Calculation
The sample size calculation for this study was based on the effect size noted in
STEMI EMS protocols, as no study has evaluated the primary outcome measure through
use of prehospital troponin. The calculation is based on Nam et al., van de Loo et al.1,2
Average door to balloon time with prehospital 12-lead ECG: 62 minutes. Average door to
balloon time control group: 96 minutes. Standard Deviation: 55. Power 80%. Type I
Error: 5%. Calculated Sample Size: 42 patients in each group. Although loss to follow-up
should be minimal within this study, accounting for loss to follow-up due to death is an
important component of prehospital research. Fifteen percent will be added to the sample
size calculation for each group; total sample size will be 49 patients in each group.
Data Collection and Analysis
Data will be collected in the EPIC electronic medical record at YNHH and BH, as
well as the computerized electronic medical record used by AMR. Paramedics will be
required to record accurate run times, 12-lead ECG, and prehospital troponin result.
Because of the potential use of the intervention in the care of the patient, blinding is not
possible for providers or patients; however, the researcher reviewing the hospital record
for data acquisition will be blinded to study group. Data will be compiled by a member of
the research team who will extract information from the medical record and assign each
patient a unique study identification number. The principal investigators will perform
subsequent analysis. Blinding of intervention and control groups will occur during
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analysis for the following outcome measures: door to balloon time, EMS contact to
balloon time, PCI status, in-hospital troponin and diagnosis of MI. Analysis of
prehospital troponin data will not be blinded.
Statistical Analysis
Analysis will be conducted using an intention-to-treat protocol. The primary
outcome measure, door to balloon time, is a continuous unpaired variable reported in
means (minutes). The statistical test for door to balloon time will be a Student’s t-test.
Statistical analysis for the secondary outcome, EMS arrival at scene to balloon time,
similarly will use the student t-test for statistical analysis. Secondary outcomes of PCI
status, diagnosis of MI, prehospital troponin, in-hospital troponin, and in-hospital
mortality are all categorical variables in this study, reported in proportions. The statistical
test for these variables will be the chi-square test. Statistical significance for all outcomes
will use a p level of 0.05.
Timeline and Resources
Upon approval by the HIC, the entire training period, data collection, and data
analysis, will be completed within two years. The Yale University School of Medicine
will provide funding for the study. Abbott i-Stat devices will be purchased and provided
to AMR for use during the study. i-Stat cartridges will also be provided by the research
team. Paramedics will be compensated at their normal hourly rate for the training
required to participate in the study, and will be awarded Continuing Medical Education
credit by the Yale-New Haven Sponsor Hospital Program. The principal investigator for
the study is Timothy N Riddell PA-SII. The faculty advisor is David Cone MD. One
independent researcher will be hired to compile data for analysis. Care of patients will be
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provided by paramedics and other EMS personnel, YNHH ED staff, and consulting
physicians.

Sample Size References:
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2.
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notification in ST-segment elevation myocardial infarction patients. Annals of
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Chapter 4: Conclusion
Advantages
The study is designed to examine delays to care in MI, the reduction of which
have been shown to decrease mortality. The primary outcome, door to balloon time, is a
well-established outcome measure.1 Door to balloon times are also easily acquired data
which do not require long-term follow-up. All data points will be collected during a
single hospital admission, and in most cases in a single day. Due to this, loss to follow-up
or patient dropout should be minimal. The proposed randomization scheme allows
control group and intervention group patients to be enrolled at the same time.
Furthermore, the cross-over design, to be completed at multiple time points within the
study, ensures that patients in both groups will be enrolled by a variety of providers and a
larger geographic area. The inclusion of both YNHH and BH also aids in the inclusion of
a more varied population. There are no obvious health risks for those involved in the
study. The prehospital troponin draw does not carry significant risk of complication, and
both control and intervention groups will receive routine EMS care.
Disadvantages
Because a prehospital activation of the cath lab based solely on positive troponin
may result in a high rate of false positives, we have elected for only a notification of the
prehospital troponin result to the receiving ED. This may limit the impact of the
intervention, but this is not unlike many of the initial studies that were conducted on
STEMI patients. Consent of patients in the prehospital settings is challenging, but a
necessary component of this study. However, we have taken measures to train
paramedics in this endeavor, and do not believe that challenges to prehospital consent
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will significantly alter the results of the study. Patients will also interact with researchers
while in the hospital, to assess whether consent was appropriately attained. Cost is also a
challenge within this study, due to the training of a large number of paramedics and the
purchasing of expensive i-Stat devices and cartridges. However, the i-Stat devices may be
repurposed at the conclusion of the study, as many hospital units are now adopting POC
devices into everyday practice.
We have elected to allow ED providers to interpret the prehospital troponin result
and decide further care independently. There will be some variability between providers,
which may affect results, however, this may be a strength in replicating the workings of a
real-world ED. It is not possible to predict the effect of including providers from both
hospitals in this study. The inclusion of two hospitals is not without challenge. However,
this is mitigated by the inclusion of BH under the YNHH HIC, as well as AMR’s
coverage of both metropolitan areas.
Clinical and Public Health Significance
It is clear that the patients with LBBB and pacemakers are undertreated and
experience more delays to treatment than those presenting with STEMI.2-4 Prehospital
troponin measurement has the potential to advance care for these patients similar to the
advent of the 12-lead ECG in the care of STEMI patients. The technology has the
potential to advance more patients to quicker life-saving treatment. The implementation
of prehospital troponin has been shown to be feasible in multiple studies.5,6 However, the
most obvious potential benefit for the measurement is in patients for whom the ECG is
unhelpful, which is the focus of this study.
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Prehospital research has unique challenges, but can result in a great improvement
of care for many acute illnesses. This study is proposed as a randomized clinical trial, a
study design that is underutilized in the prehospital setting due to its perceived
challenges.7 Our study could serve as another example of the feasibility of clinical trials
in this setting. Should this study yield significant results, it may influence further study of
prehospital troponin in a similar population. Furthermore, the study will be another test of
prehospital POC laboratory tests in general, which have the ability to aid in early
diagnosis of many acute illnesses.
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Appendices:
Appendix A: HIC Consent Form
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
200 FR. 1 (2014-4)
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN
HOSPITAL
YALE UNIVERSITY SCHOOL OF MEDICINE – BRIDGEPORT HOSPITAL

Study Title: Prehospital Quantitative Troponin for the Non-Diagnostic ECG
Principal Investigator: Timothy Riddell PA-SII; David Cone MD (Faculty Advisor)
Funding Source: Yale University School of Medicine
Invitation to Participate and Description of Project
You are invited to participate in a research study designed to look at the effect of a
prehospital troponin measurement in reducing delays to treatment for myocardial
infarction (MI). You have been asked to participate because you have presented to
emergency medical services, and your electrocardiogram is not diagnostic of MI, though
you are experiencing symptoms which may be consistent with MI.
In order to decide whether or not you wish to be a part of this research study you should
know enough about its risks and benefits to make an informed decision. This consent
form gives you detailed information about the research study, which a member of the
research team will discuss with you. This discussion should go over all aspects of this
research: its purpose, the procedures that will be performed, any risks of the procedures,
possible benefits and possible alternative treatments. Once you understand the study, you
will be asked if you wish to participate; if so, you will be asked to sign this form.

Description of Procedures
If you agree to participate in this study, you will be assigned to one of two possible
groups. In one group, no additional tests are taken, and you will receive routine care from
EMS and in the hospital. There is no additional medical risk of being assigned to this
group versus opting out of the study.
The second possible group will receive one additional test before arriving at the hospital.
Your paramedic will start an intravenous (IV) line during your routine care. This line will
be used to draw a small amount of blood (5 to 10 mL, or 1 to 2 teaspoons). Your blood
will not be mixed with other blood, and you will receive no blood products as a result of
this blood draw. This blood will be applied to a testing device called the Abbott i-Stat.
This machine will be used to test your blood for troponin, an enzyme that is released by
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the heart when it is not receiving enough blood, such as during a heart attack (MI). The
paramedic will relay the result of this test to the hospital to which you are being
transported. The result of this test will not trigger any specific treatment. Your emergency
providers will determine how to use the result of the test to determine your further
treatment, and you will be informed of all treatment decisions.
For both study groups, we will only use information from this trip to the hospital. If you
are admitted to the hospital, we will follow you during the course of this admission only.
You will receive no long-term follow-up, and we will not ask you for any additional
information once you are discharged.
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as
required by U.S. Law. This Web site will not include information that can identify you.
At most, the Web site will include a summary of the results. You can search this Web site
at any time.

Risks and Inconveniences
Group One: No Additional Prehospital Testing
There are no known physical risks associated with this arm of the study. However, your
hospital course will be compared to patients assigned to group two, which may have
better outcomes. There is the possible risk of loss of confidentiality. Every effort will be
made to keep your information confidential; however, this cannot be guaranteed.
Group Two: Prehospital Troponin Measurement
Physical risks associated with this group involve additional bleeding from IV site, and
injury to vessels as a result of the blood draw. However, an IV will be placed as part of
your routine care regardless of your participation in this study. We do not know how this
measurement will affect your care. Your hospital course will be compared to patients
assigned to group one, which may have better outcomes. There is the possible risk of loss
of confidentiality. Every effort will be made to keep your information confidential;
however, this cannot be guaranteed.

Benefits
Should you be assigned to receive the prehospital troponin test, it is possible that this may
affect your care. You may have quicker treatment and better outcomes as a result of the
test. However, this association is unknown and is the reason for the study.

Economic Considerations
You will not be compensated for your inclusion in this study. However, there is no
additional cost to you should you decide to be included. If you receive a prehospital
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troponin test, you will not be charged for this test. The supplies for the IV, as well as the
cartridge used in completing the test will be provided by the research team. The
remainder of your care in the ambulance and in the hospital will be billed normally
according to your diagnosis, treatment, and any procedure you may encounter. You will
still be responsible for any co-pays required by your insurance company for standard
treatment.
American Medical Response will receive no financial benefit from inclusion in the study.
Individual paramedics have been trained by the principal investigators, and were
compensated at their normal hourly rate for the training. Paramedics also received
continuing education credit for their training.

Treatment Alternatives/Alternatives
The only alternative is to decline participation in the study. All patients in the study will
receive routine prehospital and in-hospital care.

Confidentiality
Every effort will be made to protect your confidentiality within this study. Information
will be collected from your Electronic Medical Record (EMR). Information about your
inclusion in the study will not be entered into the EMR. All HIPAA guidelines will be
followed during the course of this study. Your information will be collected by a member
of the researcher no more than one week following your emergency visit. Once your
information is collected, you will be assigned a unique identification number for further
data analysis. At this point, only the de-identified information will be used. Your personal
information, as well as any potential identifying factors, will be removed from our
records.
Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or
State law. Examples of information that we are legally required to disclose include abuse
of a child or elderly person, or certain reportable diseases. When the results of the
research are published or discussed in conferences, no information will be included that
would reveal your identity unless your specific consent for this activity is obtained.
Representatives from the Yale Human Research Protection Program, the Yale Human
Investigation Committee (the committee that reviews, approves, and monitors research on
human subjects) may inspect study records during internal auditing procedures.
However, these individuals are required to keep all information confidential.

In Case of Injury
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If you are injured while on study, seek treatment and contact the study doctor as soon as
you are able.
Yale School of Medicine, Yale-New Haven Hospital and Bridgeport Hospital do not
provide funds for the treatment of research-related injury. If you are injured as a result of
your participation in this study, treatment will be provided. You or your insurance carrier
will be expected to pay the costs of this treatment. No additional financial compensation
for injury or lost wages is available.
You do not give up any of your legal rights by signing this form.

Voluntary Participation and Withdrawal
Participating in this study is voluntary. You are free to choose not to take part in this
study. Refusing to participate will involve no penalty or loss of benefits to which you
are otherwise entitled (such as your health care outside the study, the payment for your
health care, and your health care benefits). However, you will not be able to enroll in this
research study and will not receive study procedures as a study participant if you do not
allow use of your information as part of this study.
Withdrawing From the Study
If you do become a subject, you are free to stop and withdraw from this study at any time
during its course, which includes your time in the emergency department and your time
in the hospital should you be admitted. However, the result of the test may be used if you
receive it, and the test cannot be undone.
To withdraw from the study, you can call a member of the research team at any time and
tell them that you no longer want to take part. The researchers may withdraw you from
participating in the research if necessary.
Withdrawing from the study will involve no penalty or loss of benefits to which you are
otherwise entitled. It will not harm your relationship with your own doctors or with
Yale-New Haven Hospital, Bridgeport Hospital, or American Medical Response.
When you withdraw from the study, no new health information identifying you will be
gathered after that date. Information that has already been gathered may still be used and
given to others until the end of the research study, as necessary to insure the integrity of
the study and/or study oversight.
Questions
We have used some technical terms in this form. Please feel free to ask about anything
you don't understand and to consider this research and the consent form carefully – as
long as you feel is necessary – before you make a decision.
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Authorization
I have read (or someone has read to me) this form and have decided to participate in the
project described above. Its general purposes, the particulars of my involvement and
possible hazards and inconveniences have been explained to my satisfaction. My
signature also indicates that I have received a copy of this consent form.

Name of Subject:_____________________________

Signature:___________________________________
Relationship:________________________________
Date:______________________________________

___________________________________________
Signature of Principal Investigator

___________________
Date

or
___________________________________________
Signature of Person Obtaining Consent

___________________
Date

If you have further questions about this project or if you have a research-related
problem, you may contact the Principal Investigator Timothy Riddell (xxx-xxx-xxxx).
If, after you have signed this form you have any questions about your privacy rights,
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with
someone other than the researchers to discuss problems, concerns, and questions you
may have concerning this research, or to discuss your rights as a research subject, you
may contact the Yale Human Investigation Committee at (203) 785-4688.
THIS FORM IS NOT VALID UNLESS THE FOLLOWING BOX
HAS BEEN COMPLETED BY THE HIC OFFICE

THIS FORM IS VALID ONLY THROUGH:
____________________________________.
INITIALED:
_______________________________________
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Appendix B: Paramedic Training Outline
Course to be completed prior to research start date.
Course Directors: Timothy Riddell PA-SII, David Cone MD
Course Resources: One Abbott i-Stat device, payment for paramedics (normal hourly
rate).
This course is a 6-hour course, for which you will be compensated at your normal hourly
rate and receive 6 hours of continuing medical education credit.
Session One: 2 Hours
- Outline of Study Protocol
- HIPAA outline (supplemental HIPAA training to be completed online)
- Review of ECG: STEMI, LBBB, Paced Rhythm
- Simulated ECG Examples using Lifepak 12 and 15
- Written Quiz
Session Two: 2 Hours
- Outline of Abbott i-Stat Machines
- Outline of communication of result to receiving ED
- Outline of acquiring informed consent
- Demonstration of acquiring informed consent
- Written Quiz
Session Three: 2 Hours
- In-ED experience with i-Stat machines and ED techs
- Completed at YNHH ED only
- Paramedics must complete 3 troponin draws and tests using i-Stat machine

See Appendix C for training checklist
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Appendix C: Paramedic Training Checklist
Paramedics must complete all training to be eligible to enroll patients. Check off and sign
all completed elements.
Paramedic Name, Date ____________________
Rank at AMR ___________________________
Circle Area of Employment:

New Haven Area

Bridgeport Area

Completion of Training Course and Demonstration of Informed Consent
☐ PI Signature ___________________________

3 In-ED troponin draws with i-Stat
☐ ED Tech Signature ______________________
☐ ED Tech Signature ______________________
☐ ED Tech Signature ______________________

Completion of Online HIPAA Training
☐ PI Signature ___________________________

I certify that I have met all training requirements as outlined above.
___________________________
(Signature of Paramedic, Date)

_____________________________
(Signature of PI, Date)
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